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Abstract
The ability of aurothiomalate and auranofin to alter the production of several cellular mediators of
inflammation by RAW264.7 macrophages, was compared with each other and that of gold nanoparticles (Au
NPs). Addition of auranofin was found to have a pronounced ability to lower the production of reactive
nitrogen and oxygen species (RNS and ROS respectively), as well as interleukin-10 (IL-10) and tumour
necrosis factor (TNF), by macrophages that were subsequently treated with lipopolysaccharide (LPS) to
stimulate production of the mediators. In contrast, prior treatment of the cells with either aurothiomalate or
Au NPs had either little or no significant effect on production of RNS and ROS. Treatment of the
macrophages with Au NPs had a small effect on production of TNF by cells that were subsequently stimulated
with LPS; however, the effect was much smaller than that elicited by auranofin. Similarly, aurothiomalate had
a small but significant effect on production of IL-10. Varying the size of the Au NPs or the identity of the
protective sheath surrounding the nanoparticles did not have a significant effect on the production of RNS or
ROS by LPS-stimulated macrophages. The results of some of these investigations are discussed in the light of
other studies reported in the literature. In addition, results obtained by scanning electron microscopy and
energy-dispersive X-ray spectroscopy are presented that provide evidence for the accumulation of gold within
macrophages exposed to Au NPs.
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Abstract 15 
The ability of aurothiomalate and auranofin to alter the production of a number of cellular mediators of 16 
inflammation by RAW264.7 macrophages, was compared to each other, and that of gold nanoparticles (Au 17 
NPs). Addition of auranofin was found to have a pronounced ability to lower the production of reactive 18 
nitrogen and oxygen species (RNS and ROS, respectively), as well as Interleukin-10 (IL-10) and Tumour 19 
Necrosis Factor (TNF), by macrophages that were subsequently treated with lipopolysaccharide (LPS) to 20 
stimulate production of the mediators. In contrast, prior treatment of the cells with either aurothiomalate or 21 
Au NPs had either little or no significant effect on production of RNS and ROS. Treatment of the 22 
macrophages with Au NPs had a small effect on production of TNF by cells that were subsequently 23 
stimulated with LPS, however, the effect was much smaller than that elicited by auranofin. Similarly, 24 
aurothiomalate had a small, but significant effect on production of IL-10. Varying the size of the Au NPs, or 25 
the identity of the protective sheath surrounding the nanoparticles, did not have a significant effect on the 26 
production of RNS or ROS by LPS-stimulated macrophages. The results of some of these investigations are 27 
discussed in the light of other studies reported in the literature. In addition, results obtained by scanning 28 
electron microscopy and energy dispersive X-ray spectroscopy are presented which provide evidence for the 29 
accumulation of gold within macrophages exposed to Au NPs. 30 
 31 
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  43 
Introduction 44 
 45 
Rheumatoid arthritis (RA) is a chronic autoimmune disease that typically occurs as inflammation around the 46 
synovial joints of the body, and causes discomfort and difficulty in movement. The prevalence rate of RA in the 47 
developed world is estimated to be approximately 0.5 – 1%,[1] with the disease usually presenting between ages 48 
45 and 65,[2] and occurring more frequently in women.[3] Following a series of trials in the 1920’s and 1930’s,[4–49 
7] and confirmation in subsequent publications,[8–11] injectable gold(I) compounds such as sodium aurothiomalate 50 
became a popular choice for treatment of the disease. Several decades later the gold(I) phosphine complex 51 
auranofin was developed as a treatment for RA. Auranofin was not as effective as earlier gold drugs, but could 52 
be administered orally, and was found to have fewer or less severe side-effects.[12] Today the clinical use of 53 
gold(I) complexes for the treatment of RA has largely been superseded by other drugs, such as methotrexate, 54 
tumour necrosis factor (TNF) inhibitors, and “biologics” such as infliximab and etanercept.1,13–15 While gold 55 
complexes are still used occasionally for treatment of RA,[16,17] this is generally only for refractory forms of the 56 
disease that are unresponsive to other medications. 57 
There has also been a significant amount of recent effort focussed on the potential of gold nanoparticles (Au 58 
NPs) for a wide range of purposes in biology and medicine, including the treatment of RA.[18] One such study 59 
was published in 1997, and involved a group of ten patients suffering from a chronic form of the disease, who 60 
exhibited minimal response to several existing therapies, including gold(I) drugs.[19] The patients were then 61 
given an oral formulation of Au NPs called Aurasol, which was synthesised by the citrate method with several 62 
undisclosed “proprietary modifications.” Within one week of commencing treatment, patients showed a 63 
pronounced reduction in tenderness and swelling symptoms, which continued with further treatment. 64 
Statistically significant drops in the levels of several inflammation markers were observed by the end of the 65 
study. 66 
A subsequent study examined the effects of citrate-stabilised Au NPs on two groups of rats in which 67 
polyarthritis had been induced by injections of Mycobacterium tuberculosis, collagen, or the saturated alkane, 68 
pristane.[20] Rats treated with either aurothiomalate or Au NPs exhibited milder symptoms than the group of 69 
control rats, when arthritis was induced with the bacterium. In contrast, only rats treated with Au NPs showed 70 
improvements in their condition when symptoms of arthritis were induced by administration of collagen or 71 
pristane. 72 
The above studies highlight the potential for Au NPs to be used for the treatment of RA, and potentially other 73 
inflammatory diseases. However, many questions remain concerning how Au NPs may exert anti-arthritic 74 
effects, and their effectiveness in comparison to that of the traditional gold(I) drugs. In order to address these 75 
questions, we recently compared the cytotoxicity, extent of uptake, and distribution of several gold(I) 76 
compounds in RAW264.7 macrophages, with that of Au NPs.[21] The latter were less cytotoxic than any of the 77 
gold complexes examined, despite being incorporated to a significantly greater extent by the cells. The results of 78 
experiments conducted using synchrotron radiation X-ray fluorescence spectroscopy indicated that gold tended 79 
to accumulate in specific areas of the macrophages, regardless of what the latter were initially treated with. 80 
However, it was not possible to determine whether or not the gold was simply bound to the external surface of 81 
the macrophages, or had been internalised. Mass spectrometry was also used to examine whether or not Au NPs 82 
could bind to thioredoxin reductase, an enzyme involved in regulating the redox activity of macrophages.[22–24] 83 
These experiments were conducted in order to determine if anti-arthritic activity may arise in part because of 84 
changes to the activity of this enzyme. While all gold(I) compounds were found to bind readily to thioredoxin 85 
reductase, no such evidence was found when experiments were conducted with Au NPs. There is therefore still 86 
much that remains to be learnt about how both gold(I) compounds and Au NPs exert anti-arthritic effects. 87 
Previously there have been a number of in vitro studies that examined the effects of Au NPs upon expression of 88 
key inflammation markers.[25–31] Despite this, none of these prior investigations systematically compared the 89 
effects of Au NPs to that of clinically used gold(I) compounds, in order to draw conclusions about the likely 90 
mechanism(s) of action of the Au NPs. We report here the results of the first such systematic study, which 91 
explored the effects of both types of gold reagents on the levels of reactive oxygen and nitrogen species, tumour 92 
necrosis factor (TNF) and interleukin 10 (IL-10) produced by RAW264.7 macrophages. In the experiments 93 
presented here, the macrophages were treated with the lipopolysaccharide (LPS) in order to stimulate production 94 
of the above inflammation markers. LPS is an toll-like receptor (TLR) 4 agonist, that has been used for this 95 
purpose in a number of similar studies.[25,27,29,32–37] The Au NPs used in the experiments described herein were 96 
synthesised by the “classical” method,[38] involving reduction of gold(III) chloride by sodium citrate, which then 97 
acts as the stabilising agent for the nanoparticles. In addition to the above investigations, we present the results 98 
of further studies into the uptake of Au NPs by RAW264.7 macrophages, conducted using scanning electron 99 
microscopy (SEM) in order to determine if gold is simply bound to the surface of the cells, or becomes 100 
internalised.  101 
  102 
 103 
Results and Discussion 104 
 105 
Cellular Uptake of Au NPs by Field Emission Scanning Electron Microscopy 106 
 107 
In order to determine whether or not gold is incorporated into macrophages exposed to Au NPs, field emission 108 
scanning electron microscopy (FESEM) was employed. Figure 1 shows a series of FESEM images of an 109 
identical group of macrophages that had been treated with a solution containing 60 µM Au NPs. Each image 110 
was obtained using a different accelerating voltage. Since the use of higher voltages results in electrons with 111 
greater penetrating power, it was possible to detect gold that was deeper below the surface of the cells. Heavy 112 
metal deposits are easily identified by FESEM owing to their pronounced electron scattering properties, 113 
resulting in their appearance as white spots.[39]  Confirmation that these spots were in fact gold was provided by 114 
comparing the FESEM image of a cluster of macrophages treated with Au NPs (Supp Figure 1a), to a gold 115 
elemental map of the same cells, obtained using energy dispersive X-ray (EDX) spectroscopy (Supp Figure 1b). 116 
The gold elemental map contains clear hot spots corresponding to regions of the cells where there are higher 117 
concentrations of gold. Furthermore the overlay of the SEM micrograph and EDX gold map (Supp Figure 1c) 118 
shows that the hot spots in the latter, correspond to the distinct white spots in the former, providing strong 119 
support that there is a high gold content in the regions. 120 
The SEM image shown in Figure 1a was collected at the highest accelerating voltage used (25 kV), and shows 121 
three cells with many white spots most likely corresponding to Au NPs. Most of the spots appear somewhat 122 
diffuse, or out of focus. These are believed to derive from gold that is located below the membrane surface. In 123 
contrast, more sharply defined spots, such as that highlighted by the red arrow, are likely to correspond to 124 
surface-bound gold. Consistent with this conclusion, the latter spots remained visible in all other images 125 
obtained using lower accelerating voltages. In contrast, when the accelerating voltage was decreased, the 126 
number of diffuse, or out of focus spots arising from gold particles present below the surface of the cell 127 
decreased. Figure 1 therefore provides evidence that supports the conclusion that much of the gold present in 128 
citrate stabilised Au NPs becomes internalised by macrophages, and does not simply bind to the cell surface. 129 
The results here are generally consistent with those of an earlier study involving smaller (10 nm) Au NPs, with a 130 
similar outer stabilising layer to those examined in the current study.[40] 131 
 132 
Nitric Oxide Release 133 
 134 
The free radical nitric oxide (NO) is an important signalling molecule for a number of biological processes 135 
including vasodilation, neurotransmission and immune system regulation.[18] However, in RA it has been shown 136 
to act as a pro-inflammatory mediator.[19] This is illustrated by studies which showed that NO production is 137 
linked to generation of inflammatory cytokines, enhanced bone resorption,[18] diminished bone proliferation,[18] 138 
and chondrocyte apoptosis.[20] NO is a very short-lived species (t1/2 = 6 s) and consequently exhibits low 139 
bioavailability.[41] Therefore the amount of NO released in the following studies was inferred by determining the 140 
concentration of its major decay product, the nitrite ion (NO2‾), using the Griess assay.
[42]  141 








Fig. 1.  FESEM images of RAW264.7 macrophages treated with 60 µM Au NPs at 37 °C under an atmosphere 
of 5% CO2 for 24 h. The images are of the same cells collected at ×4300 magnification and were obtained with 
accelerating voltages of: a) 25 kV; b) 18 kV; c) 15 kV; and d) 10 kV. 
 
Initial experiments showed that treating RAW264.7 macrophages with aurothiomalate, auranofin, Au NPs or 145 
their respective solvents (vehicles), did not significantly induce NO2‾ formation (Fig. 2a). In contrast, treating 146 
the same macrophages with LPS induced formation of significant amounts of nitrite ion.  These results meant it 147 
was possible to look at the effect of pre-treatment of the macrophages with Au NPs, or gold compounds, on the 148 
amounts of NO2
- produced by subsequent treatment of the cells with LPS. The results of these experiments are 149 
presented in Fig. 2b.  150 
Pre-incubation of the macrophages with 2.5 µM aurothiomalate did not result in a statistically significant 151 
reduction in formation of NO2‾, compared to treating the cells with the corresponding vehicle (incomplete 152 
medium). When the concentration of aurothiomalate was increased to 60 µM, a drop in the production of NO2‾ 153 
was observed; however, the magnitude of the decrease was not sufficiently large for it to be deemed statistically 154 
significant. In contrast, when the cells were pre-treated with 2.5 µM auranofin, almost complete inhibition of 155 
NO2‾ production was observed after subsequent addition of LPS. Pre-incubation of the macrophages with Au 156 
NPs at both concentrations examined resulted in small (~10%), statistically insignificant decreases in the 157 












































































































































































































Fig 2. Effect of gold compounds or Au NPs, on the extent of nitrite production by RAW264.7 macrophages. a) Cells 162 
incubated with gold compounds, Au NPs or LPS at 37 °C under an atmosphere of 5% CO2 for 24 h (control experiments); b) 163 
Cells pre-incubated with gold compounds or Au NPs at 37 °C under an atmosphere of 5% CO2 for 4 h, then 0.1 µg/mL LPS 164 
added, and the cells incubated under the same conditions for a further 20 h. Nitrite concentration was then measured by the 165 
Griess assay. The error bars represent one standard deviation calculated from triplicate experiments. ** = statistically 166 
significant (P < 0.01) compared to corresponding vehicle; *** = statistically significant (P < 0.001) compared to 167 
corresponding vehicle; ns = not significant compared to corresponding vehicle (P > 0.05). 168 
 169 
The results obtained with auranofin are in good agreement with those obtained in other studies using RAW264.7 170 
cells, where the amount of LPS-induced nitrite was measured after first treating the cells with 3 or 20 µM gold 171 
complex.[34,36] In contrast, previous studies also showed that pre-treatment with aurothiomalate resulted in 172 
moderate to large decreases in NO2‾ production for RAW264.7 cells activated by LPS,
[43] as well as for murine 173 
H4 chondrocytes activated by IL-1β,[44] and non-activated peritoneal macrophages isolated from mice.[45] Whilst 174 
the results obtained using aurothiomalate in the current study may not be statistically different from those 175 
obtained with its vehicle, there appears to be a general trend which suggests that pre-incubation with even 176 
higher concentrations of this gold complex might lead to statistically relevant decreases in NO2‾ production. 177 
The absence of a significant effect of pre-treatment with Au NPs on the production of NO2‾, is in contrast to 178 
results published by Ma et. al.[27] The latter authors used a very similar methodology to that followed in the 179 
current work. However, they observed statistically significant, concentration-dependent reductions in NO2‾ 180 
production when the macrophages were pre-treated using solutions containing 10, 20 and 40 µg Au/mL of Au 181 
NPs (equivalent to 51, 102 and 203 µM Au, respectively). Since the latter solutions contained much higher 182 
concentrations of gold compared to those used in the current study, it was decided to repeat our initial 183 
experiment using Au NP pre-treatment solutions with higher concentrations. A small drop in NO2‾ production 184 
was observed for macrophages that were pre-treated with solutions containing 400 or 600 µM Au NPs (Supp 185 
Figure 2). However, the reduction in NO2‾ levels was still not statistically significant compared to the 186 
macrophage sample treated with the Au NPs vehicle. 187 
The results obtained in the current study using Au NP solutions are therefore in contrast to those reported 188 
previously.[27] The need for additional research to be carried out in this area is further highlighted by the results 189 
of a number of other published studies. For example, in one study pre-treatment of RAW264.7 macrophages 190 
with PEG-coated Au NPs caused a small increase in NO2‾ production, after the cells were subsequently treated 191 
with 0.1 µg/mL LPS.[29] In another investigation, pre-treatment of NR8383 rat macrophages with Au NPs 192 
stabilised using citrate or dihydrolipoic acid, caused no significant change in the amount of NO2‾ produced, after 193 
the cells were exposed to LPS.[28] The results of this last study mirror closely those presented here. This may be 194 
attributable to the Au NPs in both cases being stabilised using low molecular mass compounds, whereas in some 195 
of the other studies the nanoparticles had a protective polymeric coating.[27,29] The latter may have endowed the 196 
Au NPs with very different physical and chemical properties, that could have affected their ability to inhibit 197 
LPS-induced formation of NO2‾. 198 
 199 
Reactive Oxygen Species Formation 200 
 201 
The term reactive oxygen species (ROS) refers to a group of compounds containing oxygen that are involved in 202 
cell signalling and homeostasis, and includes O2, O2‾, H2O2 and •OH.
[46] Oxidative stress occurs when these 203 
molecules are produced in increased quantities, and can lead to significant damage to deoxyribonucleic acid 204 
(DNA), proteins and lipids.[47] In addition, ROS can degrade extracellular matrix materials such as collagens and 205 
proteoglycans,[48] which directly leads to joint degradation and inflammation. In patients with RA, oxidative 206 
stress is observed in the synovial fluid along with a decrease in the activity of anti-oxidant enzymes.[49] This 207 
provides support for the conclusion that production of ROS is one of the main mechanisms of pathogenesis of 208 
the disease.[50]  209 
The production of ROS in vitro was determined by measuring the extent of cellular conversion of the dye 2',7'-210 
dichlorodihydrofluorescein diacetate (DCFH2-DA) to its fluorescent form, 2',7'-dichlorofluorescein (DCF), 211 
using flow cytometry.[51,52] Addition of different concentrations of the gold compounds, or Au NPs, to the 212 
macrophages failed to induce ROS production. In contrast, addition of LPS to the cells did result in production 213 
of significant amounts of ROS (Fig. 3a). These results therefore mirrored those obtained when measuring NO 214 
production, described above. Furthermore, they enabled the following experiments to be performed, in which 215 
the effects of pre-incubation with auranofin, aurothiomalate, or Au NPs, on production of ROS by RAW264.7 216 
cells subsequently treated with LPS, to be compared. The results of these experiments are presented in Fig. 3b, 217 
and were normalised with respect to those obtained when the macrophages were treated with incomplete 218 
medium only.  219 
Treatment of the macrophages with 2.5 µM aurothiomalate had little effect on the production of ROS. However, 220 
when the concentration of aurothiomalate was increased to 60 µM, a 44% drop in ROS production was 221 
observed. As a result of the large standard deviation associated with this result, it was not statistically significant 222 
in the ANOVA analysis performed on this subset of samples. This is most likely due to the relatively large 223 
errors associated with the results for these as well as other samples, which are not uncommon for experiments 224 
conducted using the DCF assay. The results, nonetheless, suggest that treatment with aurothiomalate can 225 
decrease the amount of ROS produced by LPS-induced macrophages.  226 
Treatment of the cells with the auranofin vehicle, consisting of 1% (v/v) dimethylsulfoxide  (DMSO)/99% (v/v) 227 
incomplete medium, caused a significant (62%, P < 0.05) drop in ROS production relative to that caused by pre-228 
treatment with incomplete medium. This is most likely a result of the DMSO present in the auranofin vehicle, as 229 
the former is a known ROS scavenger.[53] A similar conclusion was reached in a previous study performed using 230 
neuroblastoma cells and the DCF assay.[54] 231 
Figure 3b shows that pre-treatment with 2.5 µM auranofin led to almost complete loss of ROS formation (P < 232 
0.05), suggesting that this compound may have a much stronger effect on production of ROS than 233 
aurothiomalate. While its effect on total ROS production does not appear to have been measured previously, 234 
auranofin has been shown to inhibit the formation of the superoxide ion (O2‾) in a number of studies using 235 
phagocytes,[55] polymorphonuclear leucocytes,[56–58] and neutrophils.[59] In addition, auranofin has been shown to 236 
quench highly reactive singlet oxygen.[60]  237 
It is also worth noting that the results presented here using aurothiomalate are consistent with literature reports, 238 
which show this gold compound has a weaker inhibitory effect on the formation of superoxide than 239 
auranofin.[55–58] It has been suggested that one mechanism by which these two compounds produce their 240 
inhibitory effects is through activation of the heterodimeric transcription factor Nrf2/small maf, that upregulates 241 
anti-oxidant proteins.[61] In addition, it has been reported that both auranofin and aurothiomalate can suppress 242 





















































































































































































































































Fig. 3. Effect of gold compounds or Au NPs on ROS production by RAW264.7 macrophages. a) Cells incubated with gold 246 
compounds, Au NPs or LPS at 37 °C under an atmosphere of 5% CO2 for 24 h (control experiments); b) Cells pre-incubated 247 
with gold compounds or Au NPs at 37 °C under an atmosphere of 5% CO2 for 4 h, then 0.1 µg/mL LPS added, and 248 
incubation continued under the same conditions for a further 20 h. ROS was measured by the DCF assay and presented as 249 
normalised MFI values at 515 nm, relative to incomplete medium. The error bars represent one standard deviation calculated 250 
from triplicate experiments. * = statistically significant (P < 0.05) compared to the corresponding vehicle; *** = statistically 251 
significant (P < 0.001) compared to the corresponding vehicle; ns = not significant compared to the corresponding vehicle (P 252 
> 0.05). 253 
 254 
When the macrophages were pre-treated with the Au NPs vehicle, or solutions containing 2.5 µM or 60 µM Au 255 
NPs, there was perhaps a minor decrease in the amount of ROS produced, compared to cells pre-treated with 256 
incomplete medium. However, further analysis of the results revealed that the effects were not statistically 257 
significant. The lack of a significant effect of Au NPs on production of ROS appears to contradict the findings 258 
of a number of other researchers. For example, one study showed that Au NPs bought from BBI (Cardiff, UK) 259 
could reduce ROS formation by human peripheral blood mononuclear cells (PBMCs).[30] A luminol-dependent 260 
chemiluminescence assay was used to measure ROS production in this study, which also showed that Au NPs 261 
with smaller diameters were more effective at inhibiting ROS formation. One key difference between this study 262 
and that described here, is that ROS formation was induced using zymosan,[30] and not LPS. This is potentially 263 
important, as zymosan is a TLR2 ligand, whilst LPS is a TLR4 ligand. Therefore their inflammatory effects may 264 
be induced through separate pathways, which in turn, the Au NPs may interact differently with. 265 
Au NPs synthesised by reaction of [AuCl4]‾ with the soil bacterium Bacillus licheniformis have also been shown 266 
to inhibit ROS formation and lipid peroxidation in diabetic mice.[31] In this study, treatment of the mice with Au 267 
NPs caused upregulation of the anti-oxidant molecule glutathione, and the anti-oxidant proteins superoxide 268 
dismutase and glutathione peroxidase. It was concluded that the greater abundance of these proteins may have 269 
been the cause of the lower ROS levels observed.[31] In another study ROS production was not changed when 270 
RAW264.7 cells were treated with poly-L-lysine-coated Au NPs for a 24 h period.[25] However, exposure to a 271 
100 µM solution of the Au NPs for 48 h did result in a significant reduction.[25] 272 
Despite the above literature studies suggesting that various types of Au NPs can inhibit ROS formation in cells, 273 
there are a number of other investigations, which did not involve the use of an inflammation-stimulating 274 
molecule, which showed they have the opposite effect. For example, the DCF assay was used to show that 275 
myeloid leukaemia and liver carcinoma cell lines treated with 30, 50 and 90 nm Au NPs purchased from 276 
CymitQuímica (Barcelona, Spain) exhibited an increase in total ROS production, coupled with strongly 277 
decreased glutathione levels and superoxide dismutase activity.[63] In addition, Au NPs (1.4 nm diameter) 278 
stabilised by triphenylphosphine monosulfate caused significant ROS formation in cervix carcinoma cells, with 279 
the effect becoming more pronounced with longer exposure periods.[64] Similarly, cervix carcinoma cells 280 
exposed to various types of 2 nm Au NPs with organic stabilizers of different lengths, showed high levels of 281 
ROS production, according to measurements performed using the DCF assay.[65] 282 
The variety of results in the literature highlights the likely importance of variations in the size and chemical 283 
composition of Au NPs on their biological activity. No literature studies appear to have looked at the effect of 284 
citrate stabilised Au NPs on ROS formation, making the results presented here distinct from those in the 285 
literature. The absence of a significant effect on ROS production, together with the minimal influence on NO 286 
production, suggests that the Au NPs studied here either do not have significant anti-inflammatory properties, or 287 
that they exert their effects through a different mechanism or mechanisms. In order to test the latter hypothesis, 288 
the effects of the Au NPs (and gold compounds) on the production of the inflammation cytokines TNF and IL-289 
10 were studied. 290 
 291 
 292 
Tumour Necrosis Factor Release 293 
 294 
High levels of TNF in synovial fluid are a characteristic feature of RA, and are strongly linked to progression of 295 
the disease. This is due to pro-inflammatory role of TNF, which stimulates the release of a large number of other 296 
inflammatory mediators.[66] In addition to cytokine release, TNF can signal oxidative burst,[67] stimulate 297 
production of prostaglandins,[68] and induce synthesis of matrix metalloproteinases.[69,70]  298 
Treatment of RAW264.7 macrophages with either 0.1 or 1 µg/mL LPS caused release of much larger amounts 299 
(~80 times) of TNF than that elicited by any of the gold compounds or Au NPs (Fig. 4a). For example, treatment 300 
of the cells with 60 µM aurothiomalate only resulted in production of 1.04 ng/mL of TNF, which was not 301 
significantly different (P > 0.05) compared to the amount of this cytokine produced when the macrophages were 302 
treated with incomplete medium (0.177 ng/mL). Similarly, treatment of the macrophages with auranofin or Au 303 
NPs failed to result in statistically significant increases in TNF production. These results indicate that the gold 304 
compounds and Au NPs do not induce production of significant amounts of this cytokine.  305 
Figure 4b shows the effects of pre-incubation of RAW264.7 macrophages with aurothiomalate, auranofin or Au 306 
NPs, on TNF production by the cells after treatment with 0.1 µg/mL LPS. Pre-incubation with 2.5 µM 307 
aurothiomalate resulted in no significant effects on the amounts of TNF produced. When the concentration of 308 















































































































































































































Fig. 4. Effect of gold compounds or Au NPs on TNF production by RAW264.7 macrophages. a) Cells treated with gold 311 
compounds, Au NPs, or LPS and incubated at 37 °C under an atmosphere of 5% CO2 for 24 h (control experiments); b) cells 312 
pre-incubated with gold compounds or Au NPs at 37 °C under an atmosphere of 5% CO2 for 4 h, then 0.1 µg/mL LPS added, 313 
and incubation continued under the same conditions for a further 20 h. TNF was measured by ELISA. The error bars 314 
represent one standard deviation calculated from triplicate experiments. * = statistically significant (P < 0.05) compared to 315 
corresponding vehicle; *** = statistically significant (P < 0.001) compared to corresponding vehicle; ns = not significant 316 
compared to corresponding vehicle (P > 0.05). 317 
 318 
The above results contradict some reports in the literature that showed aurothiomalate has a small inhibitory 319 
effect on LPS-induced TNF production in human PBMCs.[71–73] A possible explanation for this difference could 320 
be that the experiments described here were performed using a murine macrophage cell line, as opposed to 321 
PBMCs isolated directly from humans[72,73] or mice.[71] It could also arise from differences in methodology, such 322 
as differences in the length of the pre-incubation period, and use of different LPS concentrations.[71–73] It should 323 
also be noted, however, that within the literature there are reports that suggest that aurothiomalate has no effect 324 
on production of TNF. For example, one study that also investigated human PBMCs (from RA patients) showed 325 
that aurothiomalate does not alter LPS-stimulated TNF production,[74] whilst another reported that the compound 326 
does not affect TNF mRNA levels in LPS-stimulated murine macrophages.[32]  327 
Figure 4b also shows that pre-treatment of the macrophages with 2.5 µM auranofin resulted in a significant 328 
decrease (~50%, P < 0.001) in TNF production, compared to the auranofin vehicle. This is consistent with the 329 
outcomes from a previous study that showed there was inhibition of LPS-induced TNF formation in PBMCs 330 
following treatment with auranofin.[32,71] Figure 4b also indicates that pre-treatment using the auranofin vehicle, 331 
which contains 1% DMSO, may have had a significant (P < 0.05) inhibitory effect on TNF formation. A similar 332 
effect of DMSO upon TNF formation has previously been demonstrated for murine alveolar and peritoneal 333 
macrophages,[53] and is likely a result of inhibition of the transcription factor NF-κβ, which is involved in 334 
production of TNF and IL-10.[75] 335 
Pre-treatment using either 2.5 or 60 µM Au NPs resulted in small decreases in LPS-induced TNF production, 336 
that were statistically significant (P < 0.05) when compared to the amount of cytokine produced when the pre-337 
treatment was performed using the Au NPs vehicle. These results therefore appear to contrast those reported by 338 
Ma et. al,[27] who observed that Au NPs had no effect on LPS-induced TNF production. They are also 339 
inconsistent with results obtained from a study in which RAW264.7 macrophages were pre-treated with Au NPs 340 
coated with poly-N-vinylpyrrolidone, prior to the addition of LPS.[76] This once again highlights the importance 341 
that the composition of the nanoparticle shell may play in determining overall biological activity. 342 
 343 
Interleukin-10 Release 344 
 345 
It was also of interest to investigate whether the gold compounds and Au NPs might up-regulate anti-346 
inflammatory activity, as opposed to inhibiting the production of pro-inflammatory cytokines. In order to 347 
investigate this possibility, experiments were performed using IL-10. This cytokine has been shown to suppress 348 
production of the pro-inflammatory mediators IL-1α, IL-6 and IL-8,[77] as well as TNF and NO in 349 
macrophages.[78]  350 
Figure 5a shows the amounts of IL-10 produced by RAW264.7 cells exposed to aurothiomalate, auranofin, Au 351 
NPs or LPS. The results obtained indicate that none of the above gold reagents promote an anti-inflammatory 352 
process involving IL-10. This was not entirely surprising in the case of auranofin, as the results presented above 353 
showed this compound has a significant ability to suppress production of a variety of pro-inflammatory 354 
cytokines. Furthermore aurothiomalate is likely to behave similarly to auranofin, due to similarities in their 355 
uptake mechanisms and metabolites. Treatment of the macrophages with LPS, at both 0.1 and 1 µg/mL, resulted 356 
in expression of large amounts of IL-10. This is most likely due to LPS directly inducing production of pro-357 
inflammatory mediators such as TNF, which when present at sufficient levels acts as the signal for initiation of 358 
an anti-inflammatory response involving IL-10 and other cytokines. This is consistent with previous work which 359 
showed that after 12 – 24 h treatment with LPS, bone marrow derived macrophages up-regulate production of 360 
IL-10 to suppress formation of the pro-inflammatory cytokine IL-1β.[79] 361 
Whilst the results presented in Fig. 5a show that none of the gold compounds or Au NPs had a significant ability 362 
to induce IL-10 production in macrophages, the possibility remains that they may affect IL-10 production 363 
caused by other stimuli. In order to investigate this hypothesis, a series of experiments were performed to 364 
examine whether pre-treatment of macrophages with gold compounds or Au NPs, has an effect on the amount of 365 









































































































































































































Fig. 5. Effect of gold compounds or Au NPs on IL-10 production by RAW264.7 macrophages. a) Cells treated at 37 °C 370 
under an atmosphere of 5% CO2 for 24 h (control experiments); b) cells pre-incubated with gold compounds or Au NPs at 37 371 
°C under an atmosphere of 5% CO2 for 4 h, then 0.1 µg/mL LPS added, and incubation continued under the same conditions 372 
for a further 20 h. IL-10 was measured by ELISA. The error bars represent one standard deviation calculated from triplicate 373 
experiments.  = below detection limit; * = statistically significant (P < 0.05) compared to corresponding vehicle; ** = 374 
statistically significant (P < 0.01) compared to corresponding vehicle; *** = statistically significant (P < 0.001) compared to 375 
the corresponding vehicle; ns = not significant compared to corresponding vehicle (P > 0.05). 376 
 377 
Pre-treatment of the macrophages with the auranofin vehicle resulted in a significant decrease (P < 0.01) in IL-378 
10 levels compared to treatment with incomplete medium. When solutions containing auranofin itself were 379 
used, an even larger decrease in cytokine production was observed. This decrease was statistically significant 380 
compared to that caused by the auranofin vehicle alone, indicating that the DMSO present in the latter was not 381 
solely responsible for the decrease in IL-10 levels, and that the gold complex also had an effect. This result on 382 
its own is contrary to what would be expected from a compound that is used as a treatment for RA. However, it 383 
can be explained after consideration of results presented earlier. Previously it was noted that addition of 384 
auranofin caused a significant reduction in the amount of LPS-induced TNF, NO and ROS produced by 385 
RAW264.7 macrophages. The decrease in levels of each of these pro-inflammatory cytokines may therefore 386 
have been a signal to the cell that lower amounts of IL-10 are required.  387 
Figure 5b shows that pre-treatment of the macrophages with 60 µM aurothiomalate resulted in a small, but 388 
statistically significant, decrease in the amount of IL-10 produced. This may reflect the slightly lower levels of 389 
production of NO and ROS noted earlier in experiments involving high concentrations of this gold compound. 390 
In contrast, addition of aurothiomalate may have had the opposite effect on TNF levels, although the results 391 
obtained were once again not deemed to be statistically relevant. Further work is therefore required to provide a 392 
definitive answer to this question. Pre-treatment with Au NPs did not cause a statistically significant change to 393 
the amount of IL-10 produced, once again indicating a lack of interaction between the nanoparticles and the 394 
macrophages. There is therefore still further work that is required in order to fully understand the mechanism of 395 




Studies with Commercial Au NPs  400 
 401 
There was no significant anti- or pro-inflammatory behaviour observed for macrophages exposed to the Au NPs 402 
prepared for this study. This suggests the anti-arthritic activity noted previously for Au NPs might arise by 403 
mechanisms involving other mediators of inflammation. Alternatively the above results might be a consequence 404 
of differences in the size and/or composition between the nanoparticles used in the current work, and those that 405 
formed part of the earlier investigations. In order to explore the latter possibility, it was decided to repeat some 406 
of the above studies into the effects on ROS and NO, using a range of commercial Au NPs with different sizes 407 
(2 nm, 20 nm and 100 nm), or stabilised using different media (PBS or citrate buffer). The ability of these 408 
commercial Au NPs to affect the formation of the above species in LPS-stimulated macrophages was compared 409 
to that of the citrate-stabilised Au NPs synthesised for this project, as well as auranofin as a positive control (not 410 
shown). Figure 6 shows the results of these experiments.  411 
None of the commercial Au NPs resulted in a statistically significant decrease in the amount of NO2‾ produced, 412 
compared to that elicited by the Au NPs vehicle. However, it is worth noting that the 2 nm BBI Au NPs did 413 
produce a 20% reduction in the amount of NO2
−. This indicates that regardless of the size or the identity of the 414 
stabilising shell, none of the Au NPs showed a pronounced ability to alter the amount of LPS-induced NO2‾ 415 
produced. This included, once again, the citrate-stabilised Au NPs prepared for this project.  416 
The above results therefore suggest that varying the size and/or identity of the surrounding stabilising layer does 417 
not alter the ability of Au NPs to affect production of NO in macrophages that are subsequently stimulated with 418 
LPS. However, in a separate experiment in which macrophages were incubated with the different types of Au 419 
NPs in the absence of LPS, it was discovered the citrate-buffered Sigma Au NPs did increase basal cellular 420 
NO2‾ production (Supplementary Figure 3). This result therefore does provide support for the view that changes 421 
to the size and/or composition of Au NPs can have a significant impact on their biological activity.             422 
 423 
 424 
Fig. 6. Effect of pre-incubation with commercial Au NPs on LPS-induced nitrite production by RAW264.7 macrophages. 425 
Cells were pre-incubated with Au NPs at 37 °C and under an atmosphere of 5% CO2 for 4 h, and then 0.1 µg/mL LPS added 426 
and incubation continued under the same conditions for a further 20 h. Nitrite concentration was measured by the Griess 427 
assay. All Au NP treatment solutions contained 40 µM gold, with the exception of 2 nm (BBI) Au NPs, which contained 9 428 
µM gold, and the Au NP solutions produced as part of this study, which contained 60 µM gold. The error bars represent one 429 
standard deviation calculated from triplicate experiments. ns = not significant compared to corresponding vehicle. 430 
 431 
Figure 7 shows the effects of the commercial Au NPs on ROS production in LPS-stimulated macrophages. 432 
None of the commercial Au NPs produced statistically significant changes in the amount of LPS-induced ROS 433 
formation, as was also the case for the Au NPs synthesised for this project. Addition of the citrate-buffered Au 434 
NPs obtained from Sigma, and the Au NPs synthesised for this project, had similar effects on the amount of 435 
ROS produced by the macrophages. Furthermore in both cases the amount of ROS detected was perhaps higher 436 
than that observed when the Au NPs vehicle was used, although the magnitude of the changes was not 437 
statistically significant. Therefore the results obtained in this experiment are in general in good agreement with 438 





































































































































































Fig. 7. Effect of pre-incubation with commercial Au NPs on LPS-induced ROS production by RAW264.7 macrophages. 442 
Cells were pre-incubated with Au NPs at 37 °C under an atmosphere of 5% CO2 for 4 h, and then 0.1 µg/mL LPS added and 443 
incubation continued under the same conditions for a further 20 h. ROS was measured by the DCF assay and presented as 444 
normalised MFI values at 515 nm, relative to Au NPs vehicle. All Au NP treatment solutions contained 40 µM gold, with the 445 
exception of the 2 nm (BBI) Au NPs, which contained 9 µM gold and the Au NPs produced as part of this study, which 446 
contained 60 µM gold. The error bars represent one standard deviation calculated from triplicate experiments. ns = not 447 





Auranofin was shown to have powerful inhibitory effects on production of the pro-inflammatory mediators NO, 453 
ROS, and TNF, in macrophages activated using LPS. In contrast, aurothiomalate had a much weaker inhibitory 454 
effect on the production of all three mediators. These results are in agreement with those available in the 455 
literature, which indicate that auranofin is in general a stronger inhibitor of the production of inflammation 456 
mediators than aurothiomalate. 457 
Scanning electron microscopy showed evidence of internalisation of citrate stabilized Au NPs.  Despite 458 
evidence showing substantial gold uptake in a previous study,[21] and the results of electron microscopy  459 
presented here which showed gold is incorporated into macrophages treated with Au NPs, the latter did not 460 
show a pronounced ability to alter inflammatory marker expression. Both the citrate-stabilised Au NPs produced 461 
as part of this work, and a number of commercial nanoparticles, had no significant effect on the LPS-stimulated 462 
production of NO or ROS, or on induction of the anti-inflammatory cytokine IL-10. The citrate-stabilised Au 463 
NPs produced as part of this work did, however, have a small inhibitory effect on the production of the pro-464 
inflammatory cytokine TNF. It would therefore be interesting to see in future work if the use of higher 465 
concentrations of the same Au NPs, or any of the commercial nanoparticles, elicited more significant effects. 466 
There are several possible explanations for the general lack of biological activity exhibited by the Au NPs. First, 467 
Au NPs may interact with cells by a mechanism or mechanisms that do not involve the inflammation mediators 468 
investigated here. Secondly, the conditions under which the in vitro studies presented here were performed may 469 
be a poor approximation for in vivo conditions. In particular some key inflammation processes which the Au 470 
NPs might either interfere or enhance may be absent. Finally, the Au NPs used may not have produced any 471 
substantial changes to macrophage function owing to the absence of mechanisms available in vivo for activating 472 
the relatively inert Au(0) atoms. Further work is therefore required to confirm that Au NPs are efficacious anti-473 





Materials and General Methods 479 
 480 
All aqueous solutions were prepared using Milli Q™ water (18.2 MΩ, Millipore, Billerica, USA) unless 481 
otherwise specified. Sodium aurothiomalate, sodium aurothioglucose, auranofin, gold(III) chloride (99.9%), 482 
sodium citrate, sulfanilamide, N-(1-naphthyl)ethylenediamine dihydrochloride (NED), sodium nitrite and 483 
lipopolysaccharide (Escherichia coli serotype 055:B5) were obtained from Sigma-Aldrich (St. Louis, USA). 484 
Sodium hydroxide pellets (98%), sodium chloride, potassium chloride, potassium dihydrogen phosphate, 485 
sodium hydrogen phosphate, polysorbate 20 (TWEEN) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 486 
(HEPES) (all ACS grade) were obtained from Amresco (Solon, USA). DMSO (99.98%) was obtained from 487 
Fisher Scientific (Waltham, USA). Au NPs were purchased from BBI (product codes EM.GC2, EM.GC20 and 488 
EM.GC100; diameters 2, 20 and 100 nm, respectively) and Sigma-Aldrich (product codes 741965 and 753610; 489 
both have diameters of 20 nm, stabilised in citrate buffer and PBS, respectively).  490 
Mouse IL-10 and mouse TNF enzyme-linked immunosorbent assay (ELISA) kits (ELISA MAX™ Deluxe) 491 
were obtained from BioLegend (San Diego, USA). Invitrogen (Grand Island, USA) was used to obtain DCFH2-492 
DA. Enzo Life Sciences (Plymouth Meeting, USA) was used to obtain 7-aminoactinomycin D (7AAD). Foetal 493 
bovine serum (FBS, heat-inactivated) was obtained from Bovogen Biologicals (East Keilor, Australia). 494 
GlutaMAX™ and Roswell Park Memorial Institute-1640 (RPMI-1640) cell culture medium powder were 495 
obtained from Life Technologies (Carlsbad, USA).  496 
 497 
Synthesis and Characterisation of Gold Nanoparticles 498 
 499 
The synthesis and characterisation of Au NPs was carried out as described previously.[21] Milli-Q water (30 mL) 500 
was heated to near boiling and a solution of HAuCl4.3H2O (10.00 mM in water, 2.000 mL) was added.  This 501 
was followed by a solution of tri-sodium citrate (20.00 mM, 4.000 mL), resulting in the solution changing 502 
colour to red. The solution was subsequently heated for one hour, cooled to room temperature, and then 503 
transferred to a volumetric flask (50.00 mL) to which Milli-Q water was added to produce a solution with a final 504 
concentration of 400 µM Au(0), assuming complete conversion of Au(III). We have previously reported on the 505 
properties of these nanoparticles, as established using field emission scanning electron microscopy (FESEM) 506 
and other techniques.[21] FESEM showed that the nanoparticles were spherical in shape, and had diameters of 507 
between 10 and 20 nm. Consistent with this, the results of particle size analysis showed that the nanoparticles 508 
had an average diameter of 23 ± 7 nm. A single broad plasmon resonance band centred at 522 nm was present in 509 
the absorption spectrum of the nanoparticles, as expected.  510 
More concentrated solutions of Au NPs required for nitric oxide formation experiments were prepared by 511 
centrifuging the above preparation of Au NPs (11000×g, 10 min), removing the top aqueous layer, and re-512 
suspending the pellet containing the nanoparticles in a smaller volume of water. 513 
 514 
Cell Culture 515 
 516 
The adherent mouse RAW264.7 macrophage cell line was obtained from the American Type Culture Collection 517 
(Manassas, USA) as frozen permanents. The cells were maintained in RPMI-1640 medium containing 10% 518 
(v/v) FBS and 2 mM GlutaMAX™ (complete medium) at 37 °C and 5% CO2/95% air in a Revco (Twinsburg, 519 
USA) Ultima incubator.  Cells were subcultured at 90% confluence, and used between 3 and 30 passages. Cells 520 
were lifted from the surface of flasks by gentle scraping. Treatment solutions containing sodium aurothiomalate 521 
were prepared in RPMI-1640 medium containing 2 mM GlutaMAX™ (incomplete medium). Control cells were 522 
also treated with incomplete medium. Treatment solutions containing auranofin were prepared by first 523 
dissolving the metal complex in DMSO, and then diluting to the desired auranofin concentration using 524 
incomplete medium. The final concentration of DMSO in auranofin treatment solutions was 1% (v/v).  525 
Treatment solutions containing gold nanoparticles were spiked with a small volume of concentrated Dulbecco’s 526 
phosphate-buffered saline (10×D-PBS, composition defined in ‘Buffer Solutions’ below) to counteract 527 
disturbance of isotonicity due to dilution of the incomplete medium. These treatment solutions were prepared 528 
using 1.5% (v/v) 10×D-PBS, 15% (v/v) water or Au NPs solution, and 83.5% (v/v) incomplete medium. For 529 
example, a 500 µL treatment solution contained 7.5 µL 10×PBS, 75 µL of Au NPs and 417.5 µL of treatment 530 
medium. The concentration of Au NPs in treatment solutions prepared from commercial nanoparticle solutions 531 
was 40 µM. The only exception to this was stock solutions containing 2 nm Au NPs, which were originally 532 
obtained from BBI. In this case, the final concentration of the stock solution was 9 µM. 533 
Cell treatments for all experiments were performed using the following, similar steps. RAW264.7 cells were 534 
seeded into a 24-well plate (5×105/1.000 mL/well) and incubated overnight. The medium was removed by 535 
aspiration and the cells were washed three times with incomplete medium (1 mL). The relevant vehicle (500 536 
µL/well) containing LPS (a positive control treatment), gold compounds or Au NPs was added and incubated 537 
with the cells for 24 h. In other experiments, cells in incomplete medium (500 µL/well) were pre-incubated with 538 
gold compounds or Au NPs for 4 h, after which LPS (100 ng/mL) was added and the cells were incubated for a 539 
further 20 h. 540 
 541 
Buffer Solutions 542 
 543 
Dulbecco’s phosphate-buffered saline (D-PBS) consisted of KCl (2.67 mM), KH2PO4 (1.47 mM), NaCl (138 544 
mM) and Na2HPO4 (8.10 mM) at pH 7.4. 10×D-PBS contained KCl (26.7 mM), KH2PO4 (14.7 mM), NaCl 545 
(1.38 M) and Na2HPO4 (81.0 mM) at pH 7.4. Enzyme-linked immunosorbent assay (ELISA) wash buffer 546 
contained 0.5% v/v TWEEN/D-PBS. Incomplete NaCl medium contained KCl (5 mM), HEPES (10 mM) and 547 
NaCl (145 mM) at pH 7.4, while complete NaCl medium was prepared by adding glucose (5 mM) to incomplete 548 
NaCl medium. 549 
 550 
 551 
Scanning Electron Microscopy of Cells 552 
 553 
Samples were prepared on 15 mm diameter Nunc™ coverslips, which were initially washed with ethanol (70% 554 
v/v) and then complete medium, before being placed in a 60-mm cell culture dish. RAW264.7 cells in complete 555 
medium (3×106/5.00 mL/dish) were seeded into the dishes and incubated overnight. After confirming that the 556 
cells had grown to a sufficient confluence on the coverslips, the medium was removed and the cells were 557 
washed twice with incomplete medium to remove FBS. Treatment solutions (5.00 mL) containing the 558 
appropriate concentrations of Au NPs were then added to the dishes prior to incubation for 24 h. Following this 559 
period the coverslips were removed from the dishes, washed in PBS twice and then placed into glutaraldehyde 560 
solution (2% v/v in PBS) for 2 h at room temperature. At the end of this period, the coverslips were washed 561 
twice with PBS, then dehydrated by washing twice with the following ethanol solutions: 30% (v/v), 50% (v/v), 562 
70% (v/v); 10 min/solution), and then refrigerating the coverslips overnight in 70% (v/v) ethanol. The coverslips 563 
were cut to size, and then further dehydrated by adding the following ethanol solutions (once each): 70% (v/v), 564 
80% (v/v), 90% (v/v), 100% (v/v); 10 min/solution).  565 
At this point, the samples were dried by critical point drying (CPD) using an EM CPD030 instrument (Leica, 566 
Wetzlar, Germany). Briefly, the samples were submerged in ethanol at 8 °C in the chamber of the instrument, 567 
and liquid CO2 added until the chamber was full. After 15 min, the chamber was partially drained and refilled 568 
with liquid CO2, which was repeated three times. The chamber was then heated to 40 °C and CO2 gas slowly 569 
removed to dry the samples. At this point, the samples were mounted in a sample holder, coated with 10 nm of 570 
platinum and analysed using a JEOL JSM-6490LV SEM instrument for general images and a JEOL JSM-571 
7500FA FESEM instrument for variable accelerating voltage and electron dispersive X-ray (EDX) images. 572 
 573 
Nitric Oxide Formation 574 
 575 
Prior to commencement of an assay, a stock solution of sulfanilamide was prepared by dissolving 1.0 g in 100 576 
mL of 5% (v/v) HCl. In addition, a stock solution of NED was prepared by dissolving the dihydrochloride salt 577 
(0.1 g) in Milli-Q H2O (100 mL). Macrophages were first treated with gold compounds or Au NPs as described 578 
above, after which the resulting solutions were removed by aspiration and centrifuged (300×g, 5 min) to obtain 579 
cell-free supernatants. Triplicate aliquots (50 µL) of each supernatant or freshly prepared NaNO2 standards (0 – 580 
100 µM, in 10 µM increments) were added to the wells of a 96-well plate. The sulfanilamide stock solution (25 581 
µL) was added to each well using an 8-channel micropipette, followed by NED stock solution (25 µL). The 582 
plate was then incubated at room temperature for 10 min. Wells containing nitrite changed to a pink colour. The 583 
absorbance at 540 nm (A540) was measured using a Molecular Devices (Sunnyvale, USA) SpectraMAX Plus 584 
384 microplate reader. The mean absorbance of the triplicates for each sample or standard were calculated and 585 
the concentration of nitrite in each sample was interpolated from a linear standard curve (0 – 100 µM, 11 points, 586 
10 µM increments) using GraphPad Prism version 5.03 (GraphPad Software, Inc., La Jolla, USA). The 587 
experiment was performed three times, with the errors reported being the standard error of the mean for each 588 
replicate experiment. 589 
 590 
Reactive Oxygen Species Formation 591 
 592 
Stock solutions containing DCFH2-DA were dissolved in DMSO to obtain a concentration of 5 mM and were 593 
stored frozen at -20 °C in 30 µL aliquots. Experiments were performed in minimal light to prevent photodecay 594 
of the fluorescent dyes. After macrophages were treated with gold compounds or Au NPs, the treatment solution 595 
was removed by aspiration and the cells were washed three times with incomplete NaCl medium (1 mL). 596 
DCFH2-DA (500 µL, 10 µM in complete NaCl medium) or DMSO for autofluorescence control samples (500 597 
µL, 0.2% in complete NaCl medium) was added to the wells and the plate was incubated for 30 min. The cells 598 
were then washed three times with incomplete NaCl medium (1 mL) before being harvested by gentle scraping 599 
in complete NaCl medium (500 µL). The cell suspensions were then transferred to 6 mL round bottom 600 
polystyrene tubes and centrifuged (300×g, 5 min) to produce a pellet. The supernatant was decanted and the 601 
resuspended cells (<50 µL) were incubated with 7AAD (1 µL, 1 mg/mL) at room temperature for 5 min. 602 
Complete NaCl medium (300 µL) was added and the suspension analysed using a Becton Dickinson (San Jose, 603 
USA) LSR II flow cytometer. The samples were excited using a blue laser (488 nm) with emissions measured at 604 
515 nm and 695 nm corresponding to DCF and 7AAD fluorescence, respectively. A total of 10000 events were 605 
counted for each sample. Instrumental fluorescence compensation was applied in some experiments to account 606 
for ‘bleeding’ of one high intensity fluorescent marker into the other. 607 
The data was analysed using FlowJo (Tree Star, Ashland, USA), with ROS production reported as the median 608 
fluorescence intensity at 515 nm for viable cells. Viable cells were gated initially on the basis of forward scatter 609 
and side scatter, and secondly on the basis of fluorescence at 695 nm, to exclude cells with 7AAD uptake (non-610 
viable) cells. The median fluorescence intensity (MFI) at 515 nm for DMSO-treated autofluorescence control 611 
samples was subtracted from that of the relevant sample treated with DCFH2-DA to determine the amount of 612 
ROS production following each treatment. The experiment was performed five times with the errors reported as 613 
the standard error of the mean. For the LPS-induced ROS production experiment, final median fluorescence 614 
intensity values were normalised to the control sample (incomplete medium only) and reported as percentages. 615 
 616 
IL-10 and TNF Release 617 
 618 
The extent of production of the cytokines IL-10 and TNF was assessed by ELISAs performed using  kits 619 
obtained from BioLegend. These kits contained all the buffers, standards, antibodies and high-binding 96-well 620 
plates required to perform the assays, with the exception of the wash buffer. The protocol for performing the 621 
ELISA assays was provided by the manufacturer. The plates were washed by first inverting them, blotting them 622 
dry using paper towel, and then adding approximately 300 µL of wash buffer. At the end of the procedure, the 623 
absorbance of each well was measured at 450 nm and 570 nm using a Molecular Devices SpectraMAX Plus 384 624 
microplate reader. The concentration of cytokine in each sample was interpolated from a standard curve (0 – 625 
2000 pg/mL for IL-10, 0 – 500 pg/mL for TNF; 8 points per curve, 2 fold increments), which was transformed 626 
to a log scale on both axes using GraphPad Prism version 5.03. Each experiment was performed three times, 627 
with the errors reported as the standard error of the mean for each replicate experiment. 628 
 629 
Statistical Analyses 630 
 631 
Statistical significance was tested by using either a one-way ANOVA with a Tukey post-test set at 95% 632 
confidence intervals, or a two-tailed unpaired t-test with a 95% confidence interval. The tests were applied on 633 
subgroups of samples based on what vehicle was used. Specifically, both concentrations of aurothiomalate-634 
treated samples were sub-grouped with their vehicle (incomplete medium) and tested by one-way ANOVA, 635 
whilst both concentrations of Au NP-treated samples were sub-grouped with the Au NPs vehicle and also tested 636 
by one-way ANOVA. Samples treated with 2.5 µM auranofin were grouped with the auranofin vehicle 637 
treatment and tested by t-test. The auranofin and Au NPs vehicles were both grouped with incomplete medium 638 
and tested by one-way ANOVA. As such, significance reported for a sample refers to the comparison with the 639 
relevant vehicle. All statistical analyses were performed using GraphPad Prism version 5.03.  640 
 641 
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EDX and FESEM images of RAW264.7 cells treated with 60 mM Au NPs; figures showing effects of Au NPs 643 
on production of nitrite by RAW264.7 macrophages. 644 
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Supplementary Figure 1.  EDX and FESEM images of RAW264.7 cells treated with 60 µM 
Au NPs at 37˚C under an atmosphere of 5% CO2 for 24 h. Images were collected at 4300x 
magnification with an accelerating voltage of 25 kV. EDX maps were collected for 90 min: 
(a) FESEM image: (b) EDX map for gold; (c) overlap of (a) and (b). 
 
 
Supplementary Figure 2. Effect of pre-incubation with Au NPs on LPS-induced nitrite 
production by RAW264.7 macrophages. Cells were pre-incubated with various 
concentrations of Au NPs at 37 °C under an atmosphere of 5% CO2 for 4 h, then 0.1 µg/mL 
































concentration was then measured by the Griess assay. The error bars represent one standard 
deviation calculated from triplicate experiments. ns = not significant compared to Au NPs 
vehicle  (P > 0.05). 
 
 
Supplementary Figure 3: Effect of addition of commercial Au NPs on nitrite production by 
RAW264.7 macrophages. Cells were incubated with the Au NPs at 37 °C under an 
atmosphere of 5% CO2 for 24 h, and the nitrite concentration was then measured by the 
Griess assay. All Au NP treatment solutions contained 40 µM gold, with the exception of the 
2 nm (BBI) Au NPs, which contained 9 µM gold. The error bars represent one standard 
deviation calculated from triplicate experiments. *** = statistically significant (P < 0.001) 
compared to corresponding vehicle; ns = not significant compared to corresponding vehicle 
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